Profile data is unavailable for this security.
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
- Revenue in USD (TTM)31.31m
- Net income in USD-364.93m
- Incorporated2007
- Employees383.00
- LocationAgios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 649-8600
- Fax+1 (302) 655-5049
- Websitehttps://www.agios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.40bn | 136.00 | -- | 2.60 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Azenta Inc | 658.62m | -156.38m | 2.41bn | 3.30k | -- | 1.25 | -- | 3.66 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Immunitybio Inc | 1.31m | -597.65m | 2.45bn | 622.00 | -- | -- | -- | 1,874.46 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.55bn | 305.00 | -- | 4.59 | -- | 29.63 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.59bn | 525.00 | -- | 7.82 | -- | 131.60 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| CG Oncology Inc | 650.00k | -75.84m | 2.62bn | 61.00 | -- | 4.71 | -- | 4,024.62 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Janux Therapeutics Inc | 15.13m | -44.05m | 2.62bn | 64.00 | -- | 3.98 | -- | 173.11 | -0.9152 | -0.9152 | 0.3088 | 12.61 | 0.0293 | -- | -- | 236,359.40 | -8.53 | -- | -8.78 | -- | -- | -- | -291.17 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 31.31m | -364.93m | 2.65bn | 383.00 | -- | 4.01 | -- | 84.60 | -6.49 | -6.49 | 0.5568 | 11.61 | 0.0337 | 0.1687 | 10.41 | 81,738.91 | -39.28 | -29.54 | -41.94 | -31.88 | 89.33 | -- | -1,165.69 | -3,826.10 | 9.71 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Edgewise Therapeutics Inc | 0.00 | -115.88m | 2.65bn | 97.00 | -- | 5.19 | -- | -- | -1.53 | -1.53 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -26.88 | -- | -27.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Veracyte Inc | 399.58m | -54.04m | 2.68bn | 815.00 | -- | 2.36 | -- | 6.70 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Celldex Therapeutics, Inc. | 8.30m | -150.22m | 2.73bn | 160.00 | -- | 3.36 | -- | 329.28 | -2.74 | -2.74 | 0.1481 | 12.28 | 0.0145 | -- | 10.05 | 51,887.50 | -26.24 | -29.65 | -27.27 | -31.42 | -- | -- | -1,809.40 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.74bn | 630.00 | 91.17 | 5.31 | 65.25 | 3.08 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Protagonist Therapeutics Inc | 319.12m | 169.95m | 2.79bn | 125.00 | 17.95 | 5.14 | 16.31 | 8.74 | 2.64 | 2.64 | 5.22 | 9.21 | 0.6825 | -- | 449.46 | 2,849,286.00 | 36.35 | -35.90 | 39.20 | -41.36 | -- | -- | 53.26 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| PTC Therapeutics, Inc. | 900.45m | -479.52m | 2.82bn | 988.00 | -- | -- | -- | 3.13 | -6.32 | -6.32 | 11.84 | -12.75 | 0.5534 | 2.16 | 4.94 | 911,390.70 | -29.47 | -26.71 | -44.23 | -33.46 | 92.35 | 93.94 | -53.25 | -83.80 | 2.17 | -1.16 | 1.70 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Geron Corp | 1.37m | -219.55m | 2.84bn | 141.00 | -- | 9.23 | -- | 2,067.86 | -0.3595 | -0.3595 | 0.0023 | 0.5103 | 0.0032 | -- | 0.6367 | 9,737.59 | -50.78 | -51.32 | -63.77 | -64.90 | 63.00 | -- | -15,990.60 | -19,949.13 | 3.60 | -- | 0.2139 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Data as of Sep 20 2024. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD
56.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 30 Jun 2024 | 5.65m | 9.94% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.40m | 9.49% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.26m | 7.49% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 3.88m | 6.82% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 2.71m | 4.76% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.11m | 3.72% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 2.10m | 3.68% |
| Armistice Capital LLCas of 30 Jun 2024 | 2.08m | 3.65% |
| Erste Asset Management GmbH (Czech Republic)as of 31 Dec 2023 | 2.04m | 3.59% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 1.73m | 3.04% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
